Top
Summary
All studies
Mortality
Ventilation
ICU
Serious outcomes
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
 
Analgesics⏵
Antiandrogens⏵
Antihistamines⏵
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Monoclonals⏵
Mpro inhibitors⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors⏵
TMPRSS2 inh.⏵
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
Top
..
All XAV‑19 studies
..
Feedback
Home
c19early.org COVID-19 treatment researchXAV-19XAV-19 (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta
Home Adoption Other Treatments
@CovidAnalysis

Outcomes in COVID-19 XAV-19 studies

Home
@CovidAnalysis
All
Studies
Feedback
All studies   Mortality   Ventilation   ICU   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -45% 2 667 Improvement, Studies, Patients Relative Risk Mortality -45% 2 667 Ventilation -106% 1 388 ICU admission -5% 1 388 Progression -9% 2 626 RCTs -45% 2 667 RCT mortality -45% 2 667 Peer-reviewed -90% 1 388 Early -1% 1 279 Late -90% 1 388 XAV-19 for COVID-19 c19early.org May 2025 FavorsXAV-19 Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ EUROXAV Poulakou (DB RCT) -1% 1.01 [0.30-3.40] death 5/139 5/140 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.99 Early treatment -1% 1.01 [0.30-3.40] 5/139 5/140 1% higher risk POLYCOR Gaborit (DB RCT) -90% 1.90 [0.66-5.45] death 10/199 5/189 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.24 Late treatment -90% 1.90 [0.66-5.45] 10/199 5/189 90% higher risk All studies -45% 1.45 [0.65-3.21] 15/338 10/329 45% higher risk 2 XAV-19 COVID-19 studies c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.37 Effect extraction pre-specified(most serious outcome) Favors XAV-19 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ EUROXAV Poulakou (DB RCT) -1% 1.01 [0.30-3.40] 5/139 5/140 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.99 Early treatment -1% 1.01 [0.30-3.40] 5/139 5/140 1% higher risk POLYCOR Gaborit (DB RCT) -90% 1.90 [0.66-5.45] 10/199 5/189 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.24 Late treatment -90% 1.90 [0.66-5.45] 10/199 5/189 90% higher risk All studies -45% 1.45 [0.65-3.21] 15/338 10/329 45% higher risk 2 XAV-19 COVID-19 mortality results c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.37 Favors XAV-19 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ POLYCOR Gaborit (DB RCT) -106% 2.06 [1.07-3.96] 26/199 12/189 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.03 Late treatment -106% 2.06 [1.07-3.96] 26/199 12/189 106% higher risk All studies -106% 2.06 [1.07-3.96] 26/199 12/189 106% higher risk 1 XAV-19 COVID-19 mechanical ventilation result c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.03 Favors XAV-19 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ POLYCOR Gaborit (DB RCT) -5% 1.05 [0.71-1.55] 42/199 38/189 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.82 Late treatment -5% 1.05 [0.71-1.55] 42/199 38/189 5% higher risk All studies -5% 1.05 [0.71-1.55] 42/199 38/189 5% higher risk 1 XAV-19 COVID-19 ICU result c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.82 Favors XAV-19 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ EUROXAV Poulakou (DB RCT) -1% 1.01 [0.30-3.40] death 5/139 5/140 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.99 Early treatment -1% 1.01 [0.30-3.40] 5/139 5/140 1% higher risk POLYCOR Gaborit (DB RCT) -90% 1.90 [0.66-5.45] death 10/199 5/189 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.24 Late treatment -90% 1.90 [0.66-5.45] 10/199 5/189 90% higher risk All studies -45% 1.45 [0.65-3.21] 15/338 10/329 45% higher risk 2 XAV-19 COVID-19 serious outcomes c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.37 Effect extraction pre-specified(most serious outcome) Favors XAV-19 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ EUROXAV Poulakou (DB RCT) -1% 1.01 [0.30-3.40] death 5/139 5/140 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.99 Early treatment -1% 1.01 [0.30-3.40] 5/139 5/140 1% higher risk POLYCOR Gaborit (DB RCT) -90% 1.90 [0.66-5.45] death 10/199 5/189 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.24 Late treatment -90% 1.90 [0.66-5.45] 10/199 5/189 90% higher risk All studies -45% 1.45 [0.65-3.21] 15/338 10/329 45% higher risk 2 XAV-19 COVID-19 Randomized Controlled Trials c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.37 Effect extraction pre-specified(most serious outcome) Favors XAV-19 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ EUROXAV Poulakou (DB RCT) -1% 1.01 [0.30-3.40] 5/139 5/140 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.99 Early treatment -1% 1.01 [0.30-3.40] 5/139 5/140 1% higher risk POLYCOR Gaborit (DB RCT) -90% 1.90 [0.66-5.45] 10/199 5/189 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.24 Late treatment -90% 1.90 [0.66-5.45] 10/199 5/189 90% higher risk All studies -45% 1.45 [0.65-3.21] 15/338 10/329 45% higher risk 2 XAV-19 COVID-19 RCT mortality results c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.37 Favors XAV-19 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ POLYCOR Gaborit (DB RCT) -90% 1.90 [0.66-5.45] death 10/199 5/189 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.24 Late treatment -90% 1.90 [0.66-5.45] 10/199 5/189 90% higher risk All studies -90% 1.90 [0.66-5.45] 10/199 5/189 90% higher risk 1 XAV-19 COVID-19 peer reviewed studies c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.24 Effect extraction pre-specified(most serious outcome) Favors XAV-19 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ EUROXAV Poulakou (DB RCT) -1% 1.01 [0.30-3.40] death 5/139 5/140 Improvement, RR [CI] Treatment Control EUROXAV Poulakou (DB RCT) -34% 1.34 [0.58-2.88] progression 12/117 9/121 POLYCOR Gaborit (DB RCT) -90% 1.90 [0.66-5.45] death 10/199 5/189 POLYCOR Gaborit (DB RCT) 5% 0.95 [0.19-4.65] death 3/199 3/189 POLYCOR Gaborit (DB RCT) -106% 2.06 [1.07-3.96] ventilation 26/199 12/189 POLYCOR Gaborit (DB RCT) -5% 1.05 [0.71-1.55] ICU 42/199 38/189 POLYCOR Gaborit (DB RCT) -5% 1.05 [0.75-1.47] progression 53/199 48/189 XAV-19 COVID-19 outcomes c19early.org May 2025 Favors XAV-19 Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0